Business ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Obesity Treatments Clinical Research Market Competition Oncology Licensing Agreements Market Trends Artificial Intelligence Regulatory Affairs

Pfizer's 7.1% Dividend Draws Income Buyers as Patent Cliff Looms

Expiring patents on several top drugs threaten a large share of sales with new acquisitions unlikely to boost revenue until after 2028.

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

XtalPi Wins Funded Partnership to Discover Oral Small‑Molecule for Challenging GPCR

Eli Lilly Licenses AlzeCure’s Preclinical Alzheimer’s Candidate

Roche and Nurix Strike $700M Deal to Co‑Develop Oral BTK Degrader Bexobrutideg

Zealand Pharma Shares Tumble After Survodutide Phase III Shows High Dropouts

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

Pfizer and Innovent Strike Up to $10.5 Billion Oncology Collaboration

One Infusion Cuts LDL by Up to 62% in Early Gene‑Editing Trial

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

Sun Pharma Accelerates Shift to Specialty Drugs With $11.75 Billion Organon Purchase

Bristol Myers Squibb to Deploy Anthropic’s Claude Across Global Operations

Bristol Myers and Hengrui Ink Up to $15.2 Billion Drug Discovery Alliance

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Pfizer Settles With Three Generics to Keep Vyndamax Exclusive Until 2031

AstraZeneca Revives UK Plans With £300 Million for Cambridge and Macclesfield

FDA Launches First Real-Time Clinical Trial Pilot With AstraZeneca and Amgen

Lilly and Profluent Strike AI Gene-Editing Pact Worth Up to $2.25 Billion

Boehringer Ingelheim to Invest £150 Million in London AI Drug Discovery Centre